Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142129 · ClinicalTrials.gov registry record · Phase 2
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
A Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 2
- Study locations
NCT00142129 is a Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 27 participants, below the 107-participant average among 18 other Lymphoplasmacytic Lymphoma trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00142129, a Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate how tumors in patients with Waldenstrom's macroglobulinemia respond to treatment with bortezomib (Velcade) and to see what effects (good and bad) it has on the cancer.
Conditions Studied
Interventions
- DRUG Bortezomib (Velcade)
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Center - Boston
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2003-12 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142129
The ClinicalTrials.gov registry entry for NCT00142129 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 107-participant average among 18 other Lymphoplasmacytic Lymphoma trials with a reported enrollment target (75% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoplasmacytic Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Bortezomib (Velcade) is the first listed.
NCT00142129 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00142129 about?
NCT00142129 is a clinical study titled "Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia". The purpose of this study is to evaluate how tumors in patients with Waldenstrom's macroglobulinemia respond to treatment with bortezomib (Velcade) and to see what effects (good and bad) it has on the cancer.
What is the current status of trial NCT00142129?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2003-12. Estimated completion is 2007-06.
What conditions does trial NCT00142129 study?
This clinical trial studies the following conditions: Lymphoplasmacytic Lymphoma, Waldenstrom's Macroglobulinemia.
What interventions are being tested in trial NCT00142129?
The interventions under investigation include: Bortezomib (Velcade) (DRUG).
Who is sponsoring clinical trial NCT00142129?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00142129 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoplasmacytic Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
RECRUITING · Phase 2
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
-
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Lymphoplasmacytic Lymphoma
All registered trials for this condition
Waldenstrom's Macroglobulinemia
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.